Article Text
PDF
Statistics from Altmetric.com
Ramy A Mahmoud
Correspondence to: Ramy A Mahmoud, ETHICON, Inc, PO Box 151, US Highway 22 West, Room E314, Somerville, NJ 08876, USA; rmahmou@ethus.jnj.com
QUESTION
Question:
How effective is augmentation with low-dose risperidone for treatment-resistant depression in adults?
Patients:
274 outpatients aged 18–65 years with DSM-IV major depressive disorder who did not respond to standard antidepressant monotherapy during 4 weeks’ treatment prior to randomisation (non-response defined as Clinical Global Impression-Severity of Illness (CGI-S) score ⩾4 and Carroll Depression Scale score ⩾20). Exclusions: pregnancy; substance or alcohol use disorder; current use of tricyclic antidepressant, monoamine oxidase inhibitor, antiepileptic, or mood stabiliser; suicidal risk; serious medical or neurological illness; treatment for attention deficit/hyperactivity disorder or narcolepsy.
Setting:
Outpatient clinics in public and private care settings and psychiatric centres in the USA; recruitment October 2004 to November 2005.
Intervention:
Six weeks’ treatment augmentation with low-dose risperidone (0.25 mg for the first 3 days, 0.5 mg on days 4–15, 1.0 mg on days 16–28) or placebo. If there was no response by day 29, dose could be increased to 2 mg daily at the investigator’s discretion or …
Footnotes
Source of funding: Ortho-McNeil Janssen Scientific Affairs.
▸ Additional notes are published online only at http://ebmh.bmj.com/content/vol11/issue3
Footnotes
Competing interests: JB has worked as a consultant for Bristol-Myers Squibb and Jazz Pharmaceuticals, and as a researcher for Bristol-Myers Squibb, GlaxoSmithKline, Pamlab, Inc, Pfizer and Wyeth Ayerst..
Request Permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.